TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

TG Therapeutics, Inc.NASDAQ: TGTX

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) declines year over year

Q3 FY2026 weighted avg shares (diluted) of 155.93M shares fell 3.2% year over year, behind the -2.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.9% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -3.2% toward the trailing-twelve-month pace of -2.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
155.93M-0.9% QoQ
Last fiscal yearDec 2025
161.41M+0.7% YoY
LTMSep 2026
158.16M-2.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.2%——
1 year+0.7%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
161.41M USD
Year-over-year change
+0.7%
4-year CAGR
+5.1%

Weighted Avg Shares (Diluted) vs competitors

How TGTX compares with its peers on the latest reported figures

  • TGTX's LTM Sep 2026 weighted avg shares (diluted) of 158.16M shares is the 2nd highest of the 9 companies compared; the peer median is 78.76M shares.
  • Its year-over-year change of -2.2% is the lowest of 7, against a peer median of +9.7%.
  • Over three fiscal years its annual growth of +6.0% compares with a peer median of +5.7%.
TGTX Competitors Peer median
Weighted Avg Shares (Diluted) for TGTX and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
TGTXTG Therapeutics, Inc.LTM Sep 2026158.16M -2.2%+6.0%
ADCTADC Therapeutics S.A.LTM Mar 2026138.66M +34.3%+17.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+3.9%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.59M +22.4%+19.7%
XNCRXencor, Inc.LTM Jun 202674.94M +5.1%+7.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
ADAGAdagene Inc.LTM Jun 202435.23M —+2.9%
Peer median (excluding TGTX) 78.76M+9.7%+5.7%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.